KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Debt (2018 - 2025)

Castle Biosciences' Total Debt history spans 5 years, with the latest figure at $10.1 million for Q4 2025.

  • For Q4 2025, Total Debt changed 0.34% year-over-year to $10.1 million; the TTM value through Dec 2025 reached $10.1 million, changed 0.34%, while the annual FY2025 figure was $10.1 million, 0.34% changed from the prior year.
  • Total Debt for Q4 2025 was $10.1 million at Castle Biosciences, roughly flat from $10.0 million in the prior quarter.
  • Across five years, Total Debt topped out at $20.8 million in Q1 2022 and bottomed at $1.1 million in Q1 2025.
  • The 3-year median for Total Debt is $10.0 million (2024), against an average of $10.2 million.
  • The largest YoY upside for Total Debt was 0.34% in 2025 against a maximum downside of 88.89% in 2025.
  • A 3-year view of Total Debt shows it stood at $20.8 million in 2022, then plummeted by 51.93% to $10.0 million in 2024, then increased by 0.34% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Total Debt are $10.1 million (Q4 2025), $10.0 million (Q3 2025), and $10.0 million (Q2 2025).